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Methods: Patients with stage I to IV NSCLC that were treated with 
geﬁtinib or erlotinib after failure of 1st and 2st-line platinum-based 
chemotherapy were subjected to this analysis. Genomic DNA was 
isolated from parafﬁn-embedded tumor specimens, ampliﬁed for EGFR 
(exons 18, 19, 20 and 21) by touchdown hemi-nested polymerase chain 
reaction and sequenced in both sense and antisense directions. RECIST 
criteria were used to assess response to chemotherapy and TKIs.
Results: This mono-istitutional retrospective analysis was conducted 
on 103 pts from July 2002 to November 2006. Median age was 60 
yrs (range 25-81.5), M/F: 59/44, ECOG-PS 0/1/2/3:68/30/4/1; stage: 
I/II/III/IV 4/5/35/59; adeno/bronchioloalveolar/squamous/large-cells/
other:66/9/20/3/5;never/former/current smokers: 26/20/36. EGFR mu-
tations were detected in 19 pts (18.5%); 13 pts (13.8%) had deletional 
mutations in exon 19, 3 pts (2.9%) had point mutations in exon 20 (one 
patient had two mutations) and 3 pts (2.9%) had missense mutations in 
exon 21. No associations were detected between EGFR mutations and 
adeno/bac histotype (p=0.51), smoke (p=0.23) and gender (p=0.14). 
Disease control rate to TKIs therapy was 54.4%, including 1 complete 
(pt. with EGFR mutations), 21 partial response and 34 stable disease 
and objective response rate was 42%. Median time to progression was 
4.4 months and median survival was 23.7 months. Patients with EGFR 
mutations had a signiﬁcant impact on response rate (PR/CR, 42% 
p=0.015) to TKIs. Instead EGFR mutations did not inﬂuence the re-
sponse to chemotherapy. Cox’s multivariate analysis including gender, 
smoke, stage and histotype showed that EGFR mutations did not reach 
statistical signiﬁcance for progression free survival (PFS) (p=0.52) and 
overall survival (OS) (p=0.50); only adeno/bac histotype was a prog-
nostic factor for longer PFS (p=0.01) and OS (p=0.04).
Conclusions: In our experience EGFR mutations seem to inﬂuence 
response rate in pts treated with TKIs after platinum-based chemother-
apy. These data will be more thoroughly deﬁned by ﬂuorescence in situ 
hybridization analysis of EGFR gene copy number, measurement of 
EGFR and phosphorylated Akt (p-Akt) protein expression by immuno-
histochemistry and KRAS mutations. 
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Background: A randomised phase III trial (Eastern Co-operative 
Oncology Group 4599) has demonstrated that bevacizumab in combi-
nation with standard ﬁrst-line chemotherapy (carboplatin/paclitaxel) 
signiﬁcantly improves outcomes in patients with advanced or recurrent 
non-small cell lung cancer (NSCLC). The MO19390 trial is investigat-
ing the safety proﬁle of bevacizumab in combination with standard 
ﬁrst-line chemotherapy regimens.
Methods: Approximately 2,000 patients from 400 centres world-
wide will be enrolled in this open-label, single-arm trial. The primary 
endpoint is to assess the safety proﬁle of bevacizumab when combined 
with chemotherapy as ﬁrst-line treatment for advanced or recurrent 
NSCLC. Secondary endpoints include time to disease progression and 
overall survival. Eligible patients must have histologically or cytologi-
cally documented locally advanced, metastatic or recurrent non-squa-
mous NSCLC, Eastern Co-operative Oncology Group performance 
status (PS) 0-2 and adequate haematological, liver and renal function. 
Patients with a history of haemoptysis, evidence of tumour invading 
major blood vessels or evidence of CNS metastases are ineligible. 
The selection of the bevacizumab dose for this safety study (15mg/kg 
every 3 weeks) was based on the ECOG 4599 trial. Eligible patients 
will receive bevacizumab in combination with a standard ﬁrst-line 
chemotherapy regimen, which may include non-platinum doublets if 
the centre has speciﬁc experience with an established regimen, and may 
include single-agent chemotherapy for elderly patients or those with PS 
2. Following a maximum of 6 cycles of chemotherapy plus bevaci-
zumab (15mg/kg on day 1 and then every 3 weeks), non-progressing 
patients will continue to receive bevacizumab as maintenance therapy 
until disease progression or unacceptable toxicity. During treatment, 
the incidence of all serious and non-serious bevacizumab-associated 
adverse events will be reported. Additional information about adverse 
events of special interest will be collected (hypertension, proteinuria, 
wound-healing complications, arterial or venous thromboembolic 
events, haemoptysis, CNS bleeding, other haemorrhages, gastrointesti-
nal perforations and congestive heart failure). The planned sample size 
will enable investigation of non-frequent adverse events. All patients 
will be followed up for survival at study end.
Results: Trial enrolment commenced in August 2006. Recruitment is 
expected to continue for approximately 12 months in each participating 
country. As of March 2007, 240 patients have been enrolled (ITT popu-
lation=128) from 17 countries. Median age is 60y (range 28-83). Pa-
tient characteristics (%) are: male/female 64.1/35.9; non-smoker/ex- or 
current-smoker 25.2/74.8 (no data <1); ECOG PS 0/1/2 42.5/53.5/3.9 
(no data <1); adenocarcinoma/other 81/19; stage IIIb/IV 24.4/75.6 (no 
data <1); chemotherapy backbone: cisplatin-gemcitabine/carboplatin-
paclitaxel/carboplatin-gemcitabine/cisplatin-paclitaxel/monotherapy/
non-platinum doublets/other 28.9/25.0/10.9/8.6/3.9/2.3/20.4. To date, 
a total of 61 serious adverse events (SAEs) have been reported, 15 of 
which are considered by the investigator to be study drug related. Six 
of these 15 events have now been resolved. No haemoptysis SAEs have 
been reported to date. 
Conclusions: The large sample size will provide valuable information 
on the safety proﬁle of bevacizumab. Preliminary safety and efﬁcacy 
analyses will be presented at the meeting.
